Open access
Jul 2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.
TPFS6 remained prognostic for OS and PFS even after accounting for PD/SD, underscoring the impact of severe toxicity on subsequent survival, and may predict long-term outcomes following CAR-T therapy.
A. Saha, Junmin Whiting, R. Mohty et al.
· Bone Marrow Transplantation · 0 citations